ProMetic Life Sciences Inc. (PLI) Receives Overweight Rating from Cantor Fitzgerald
ProMetic Life Sciences Inc. (TSE:PLI)‘s stock had its “overweight” rating restated by equities researchers at Cantor Fitzgerald in a report issued on Monday. Cantor Fitzgerald also issued estimates for ProMetic Life Sciences’ FY2017 earnings at ($0.19) EPS and FY2018 earnings at ($0.11) EPS.
A number of other research analysts have also weighed in on the company. National Bank Financial decreased their price objective on ProMetic Life Sciences from C$2.50 to C$2.00 and set a “sector perform” rating on the stock in a report on Wednesday, November 15th. Royal Bank Of Canada decreased their price objective on ProMetic Life Sciences from C$4.00 to C$3.50 and set an “outperform” rating on the stock in a report on Wednesday, August 16th. Finally, TD Securities decreased their price objective on ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating on the stock in a report on Wednesday, August 16th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. ProMetic Life Sciences presently has an average rating of “Buy” and an average price target of C$3.50.
ProMetic Life Sciences (TSE:PLI) opened at C$1.40 on Monday. ProMetic Life Sciences has a fifty-two week low of C$1.12 and a fifty-two week high of C$2.69.
TRADEMARK VIOLATION WARNING: “ProMetic Life Sciences Inc. (PLI) Receives Overweight Rating from Cantor Fitzgerald” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/11/22/prometic-life-sciences-inc-pli-receives-overweight-rating-from-cantor-fitzgerald.html.
ProMetic Life Sciences Company Profile
Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.